Dr Reddy’s Laboratories had dipped over 3% at Rs 1,599, extending its previous day’s around 1% fall, on reporting a slightly lower-than-expected 28% year-on-year (y-o-y) growth in consolidated net profit at Rs 336 crore for the quarter ended June 2012. Net sales grew 28% at Rs 2,541 crore on y-o-y basis.
Analysts on average estimated the net profit at Rs 367 crore on net sales of Rs 2,560 crore.
“Gross profit margin at 53% in Q1 FY13 remained flat versus Q1 FY12. In the quarter, the company had a foreign exchange loss of Rs 20.9 crore, compared with a gain of Rs 15.8 crore a year ago,” Dr Reddy's Laboratories said in a filing.
The stock opened at Rs 1,640 and hit a low of 1,598 on the National Stock Exchange. A combined 356,378 shares have changed hands on the counter so far on both the exchanges.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app